PubMed

Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients.

Forcheron F, Cachefo A, Thevenon S, Pinteur C, Beylot M.

Diabetes. 2002 Dec;51(12):3486-91.PMID: 12453904 [PubMed - indexed for MEDLINE]Related articlesFree article

Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.

Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K.

Diabetes Res Clin Pract. 2004 May;64(2):137-51.PMID: 15063607 [PubMed - indexed for MEDLINE]Related articles

Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.

Iovine C, Lilli S, Gentile A, Patti L, Di Marino L, Cipriano P, Riccardi G, Rivellese AA.

Eur J Clin Invest. 2006 Aug;36(8):560-5.PMID: 16893378 [PubMed - indexed for MEDLINE]Related articles

Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.

Vega GL, Cater NB, Hadizadeh DR 3rd, Meguro S, Grundy SM.

Clin Pharmacol Ther. 2003 Sep;74(3):236-44.PMID: 12966367 [PubMed - indexed for MEDLINE]Related articles

Hepatic lipogenesis and cholesterol synthesis in hyperthyroid patients.

Cachefo A, Boucher P, Vidon C, Dusserre E, Diraison F, Beylot M.

J Clin Endocrinol Metab. 2001 Nov;86(11):5353-7.PMID: 11701705 [PubMed - indexed for MEDLINE]Related articlesFree article

Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

Lambert G, Ancellin N, Charlton F, Comas D, Pilot J, Keech A, Patel S, Sullivan DR, Cohn JS, Rye KA, Barter PJ.

Clin Chem. 2008 Jun;54(6):1038-45. Epub 2008 Apr 24.PMID: 18436719 [PubMed - indexed for MEDLINE]Related articlesFree article

Reductions in plasma cholesterol levels after fenofibrate treatment are negatively correlated with resistin expression in human adipose tissue.

Jové M, Planavila A, Cabrero A, Novell F, Ros E, Zambón D, Laguna JC, Carrera MV.

Metabolism. 2003 Mar;52(3):351-5.PMID: 12647275 [PubMed - indexed for MEDLINE]Related articles

Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

Nesto RW.

Am J Cardiovasc Drugs. 2005;5(6):379-87. Review.PMID: 16259526 [PubMed - indexed for MEDLINE]Related articles

Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.

Brisson D, Ledoux K, Bossé Y, St-Pierre J, Julien P, Perron P, Hudson TJ, Vohl MC, Gaudet D.

Pharmacogenetics. 2002 Jun;12(4):313-20.PMID: 12042669 [PubMed - indexed for MEDLINE]Related articles

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators.

Lancet. 2005 Nov 26;366(9500):1849-61. Erratum in: Lancet. 2006 Oct 21;368(9545):1415. Lancet. 2006 Oct 21;368(9545):1420. PMID: 16310551 [PubMed - indexed for MEDLINE]Related articles

Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.

Wu TJ, Ou HY, Chou CW, Hsiao SH, Lin CY, Kao PC.

Ann Clin Lab Sci. 2007 Spring;37(2):158-66.PMID: 17522372 [PubMed - indexed for MEDLINE]Related articles

HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia.

Guan JZ, Tamasawa N, Murakami H, Matsui J, Tanabe J, Matsuki K, Yamashita M, Suda T.

J Atheroscler Thromb. 2008 Feb;15(1):20-5. Epub 2008 Feb 9.PMID: 18270459 [PubMed - indexed for MEDLINE]Related articlesFree article

Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control.

Tan CE, Chew LS, Tai ES, Chio LF, Lim HS, Loh LM, Shepherd J.

Atherosclerosis. 2001 Feb 1;154(2):469-74.PMID: 11166781 [PubMed - indexed for MEDLINE]Related articles

Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.

Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, Hoffmann MM, Baumstark MW, Wieland H, März W.

Exp Clin Endocrinol Diabetes. 2004 May;112(5):241-7.PMID: 15146369 [PubMed - indexed for MEDLINE]Related articles

Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.

Foucher C, Rattier S, Flavell DM, Talmud PJ, Humphries SE, Kastelein JJ, Ayyobi A, Pimstone S, Frohlich J, Ansquer JC, Steiner G; DAIS investigators.

Pharmacogenetics. 2004 Dec;14(12):823-9.PMID: 15608561 [PubMed - indexed for MEDLINE]Related articles

A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?

Steiner G.

Treat Endocrinol. 2005;4(5):311-7. Review.PMID: 16185099 [PubMed - indexed for MEDLINE]Related articles

The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.

Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.

Metabolism. 2005 May;54(5):677-81.PMID: 15877299 [PubMed - indexed for MEDLINE]Related articles

Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.

Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.

Kardiol Pol. 2004 Jun;60(6):567-77. English, Polish. PMID: 15334157 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.

Seber S, Ucak S, Basat O, Altuntas Y.

Diabetes Res Clin Pract. 2006 Jan;71(1):52-8. Epub 2005 Jul 11.PMID: 16009445 [PubMed - indexed for MEDLINE]Related articles

Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate.

Brouillette C, Bossé Y, Pérusse L, Gaudet D, Vohl MC.

J Hum Genet. 2004;49(8):424-32. Epub 2004 Jul 13.PMID: 15249972 [PubMed - indexed for MEDLINE]Related articles